Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR65 | Q8IYL9 | 10/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390624 | 1.00 | GPR65 (0.49) | GPR65CCR2KCNH2TSHRSLC6A3 | |
| SCHEMBL30390984 | 1.00 | GPR65 (0.49) | GPR65CCR2KCNH2TSHRSLC6A3 | |
| SCHEMBL26879883 | 0.93 | GPR65 (0.49) | GPR65CCR2KCNH2TSHRSLC6A3 | |
| SCHEMBL30390699 | 0.91 | GPR65 (0.48) | GPR65CCR2KCNH2TSHRRECQL | |
| SCHEMBL26879873 | 0.91 | GPR65 (0.48) | GPR65CCR2KCNH2TSHRRECQL | |
| SCHEMBL30391181 | 0.91 | GPR65 (0.48) | GPR65CCR2KCNH2TSHRRECQL | |
| SCHEMBL30391848 | 0.91 | GPR65 (0.48) | GPR65CCR2KCNH2TSHRRECQL | |
| SCHEMBL30390123 | 0.89 | GPR65 (0.52) | GPR65CCR2KCNH2MAPT | |
| SCHEMBL30390605 | 0.89 | GPR65 (0.52) | GPR65CCR2KCNH2MAPT | |
| SCHEMBL26879877 | 0.89 | GPR65 (0.52) | GPR65CCR2KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373989-A1 | N-PHENYLAMINOCARBONYL PYRIDINO-, PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-11-23 | — | — | US | disclosed |
| US-20230373989-A1 | N-PHENYLAMINOCARBONYL PYRIDINO-, PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-11-23 | — | — | US | disclosed |
| EP-4161642-A1 | N-PHENYLAMINOCARBONYL PYRIDINO-, PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | Pathios Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373989-A1 | N-PHENYLAMINOCARBONYL PYRIDINO-, PYRIMIDINO AND BENZO-TROPANES AS MODULATORS OF GPR65 | GPR65, GPR55, GPR68 | GPR65 1/4885CCR2 137/4885KCNH2 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.